Global $6+ Billion Cell Therapy Manufacturing Markets, Analysis & Forecasts, 2016-2020 & 2021-2026

Dublin, IRELAND


Dublin, March 16, 2022 (GLOBE NEWSWIRE) -- The "Global Cell Therapy Manufacturing Market, By Therapy (T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies), By Source of Cell, By Scale of Operation, By Source, By Application, By End User, By Region, Competition Forecast and Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

The Global Cell Therapy Manufacturing Market was valued at USD3123.44 million in the year 2020 and is anticipated to grow with a CAGR value of 12.0% in the forecast period, 2022-2026 to reach market value of USD6015.09 million by 2026F.

The market growth can be attributed to advancing biopharmaceutical industries across the globe. Moreover, increasing dependency on cell therapy and thus therapeutics & pharmaceutical products for the efficient treatment of the patients suffering from critical diseases and conditions is also supporting the growth of the Global Cell Therapy Manufacturing Market in the next five years.

Additionally, growing prevalence of chronic diseases like cardiovascular diseases, cancer disease, along with lifestyle diseases like obesity, diabetes that further deteriorates immunity of the humans further contributes to the growth of the Global Cell Therapy Manufacturing Market in the future five years.

Recent instance of COVID-19 outbreak that caused millions of deaths worldwide has created a demand for advanced cell therapy manufacturing to devise pharmaceuticals, vaccines, etc. Significant development and advancement in cell-based therapies for skin rejuvenation and tendon regeneration are further driving the growth of the Global Cell Therapy Manufacturing Market in the forecast period.

The Global Cell Therapy Manufacturing Market is segmented by therapy, source of cell, scale of operation, source, application, end-user, company, and regional distribution. Based on application, the market is further divided into oncology, cardiovascular diseases, orthopedic diseases, and others.

Oncology sub-segment is anticipated to hold more than 50% of the revenue shares of the market and dominate the application-based market segmentation in the upcoming five years. The growth can be attributed to increasing instances of various types of cancer in the global population. Moreover, increased technological advancement and consistent cell therapy-based research for the treatment of cancer is further anticipated to support the market growth.

Objective of the Study:

  • To analyze and estimate the market size of the Global Cell Therapy Manufacturing Market from 2016 to 2020.
  • To estimate and forecast the market size of the Global Cell Therapy Manufacturing Market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast the Global Cell Therapy Manufacturing Market based on therapy, source of cell, scale of operation, source, application, end-user, company, and regional distribution.
  • To identify dominant region or segment in the Global Cell Therapy Manufacturing Market.
  • To identify drivers and challenges for the Global Cell Therapy Manufacturing Market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Cell Therapy Manufacturing Market.
  • To identify and analyze the profile of leading players operating in the Global Cell Therapy Manufacturing Market.
  • To identify key sustainable strategies adopted by the market players in the Global Cell Therapy Manufacturing Market.

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Therapy Manufacturing Market.

  • Novartis AG
  • F. Hoffmann La Roche AG
  • Gilead Sciences, Inc.
  • Thermo Fischer Scientific, Inc.
  • Catalent, Inc.
  • JSR Life Sciences LLC (KBI Biopharma Inc)
  • Waisman Center (Waisman Biomanufacturing)
  • Cell and Gene Therapy Catapult
  • Merck KGaA
  • Lonza Group
  • Oxford Biomedica Plc
  • WuXi AppTec
  • Charles River Laboratories International Inc.
  • Institut Merieux (ABL Inc.)
  • BioCentriq
  • Centre for Commercialization of Regenerative Medicine (CCRM)
  • Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics)
  • Amgen Inc.
  • Bluebird Bio Inc.
  • Takeda Pharmaceutical Company Limited

Report Scope:

Years considered for this report:

  • Historical Years: 2016-2019
  • Base Year: 2020
  • Estimated Year: 2021
  • Forecast Period: 2022-2026

Global Cell Therapy Manufacturing Market, By Therapy

  • T-Cell Therapies
  • Dendritic Cell Therapies
  • Tumor Cell Therapies
  • Stem Cell Therapies

Global Cell Therapy Manufacturing Market, By Source of Cell

  • Autologous
  • Allogenic

Global Cell Therapy Manufacturing Market, By Scale of Operation

  • Preclinical
  • Clinical
  • Commercial

Global Cell Therapy Manufacturing Market, By Source

  • In-House
  • Contract Manufacturing

Global Cell Therapy Manufacturing Market, By Application

  • Oncology
  • Cardiovascular Diseases
  • Orthopedic Diseases
  • Others

Global Cell Therapy Manufacturing Market, By End-User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Others

Global Cell Therapy Manufacturing Market, By Region

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Australia
  • India
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • Israel
  • South Africa
  • Saudi Arabia
  • UAE

For more information about this report visit https://www.researchandmarkets.com/r/27k0wr


Attachment

 
Global Cell Therapy Manufacturing Market

Coordonnées